More Access and Evidence Articles

Access and Evidence

Merck Settles Vytorin Clinical Trials Data Lawsuit For US$688 Million

Lucy Brake, (Feb 19, 2013)

In what is claimed to be one of the top 25 securities class action settlements of all time, Merck & CO has settled investor claims that the company withheld negative data from clinical trials on Vytorin.
Access and Evidence

Plan to Cut Drug Costs Will Hurt Pharma Industry’s Bottom-Line

Lucy Brake, (Feb 18, 2013)

President Barack Obama is targeting drug rebates in efforts to reduce ever rising Medicare costs. This could potentially result in billions of dollars in lost profits for the drug industry.
Access and Evidence

New Infrastructure Is Needed to Create Value

Jeff Elton, (Feb 18, 2013)

Developing and commercializing personalized medicine requires that top executives at life sciences companies become value managers and support a value management infrastructure, Jeff Elton examines and explains...
Access and Evidence

Breaking Through to the Frontline

Matthew Wood, (Feb 15, 2013)

Certain medicines have been given a new type of status by the Food and Drug Administration (FDA), better known as Breakthrough Therapy Designations.
Access and Evidence

Pharma Still in Love with India Despite Aggressive Legislation

Anonymous, (Feb 14, 2013)

Big Pharma will continue to invest in India in spite of governmental decisions taken in past months that have favoured generics over branded drugs.
Access and Evidence

The Next Emerging Market – 30 Billion Reasons to Focus on Africa

Zuzanna Fimińska, (Feb 13, 2013)

With rapid economic growth, pharmaceutical spending expected to reach US$30 bln by 2016, and the recently launched Federation of African Pharmaceutical Manufacturers Associations, Africa is beginning to show promise as the next big emerging market for Pharma.
Access and Evidence

New 3-D Control Offers Innovative Drug Discovery Route

Lucy Brake, (Feb 11, 2013)

A collaborative team of scientists at Yale University has demonstrated a new and highly versatile approach for quickly assembling drug-like compounds.
Access and Evidence

“Open Source” Drug Discovery - €196M Program Launched

Ben Steele, (Feb 8, 2013)

Major pharma firms have joined together in a consortium with academics and SMEs that will invest €196 million in a new project to give a boost to ‘open-source’ drug discovery in the EU.
Access and Evidence

Mandatory Compensation for Clinical Trial Injuries in India

Louise Kelly, (Feb 7, 2013)

A lack of reasonable care and financial compensation has long been associated with clinical trials conducted in India, but this situation is set to change dramatically as the Indian government introduce stricter compensation laws & regulations for clinical trials.
Access and Evidence

Lifting the Veil: GSK Becomes the First to Share Clinical Trials Data

Zuzanna Fimińska, (Feb 6, 2013)

After months of public demands and resistance from the industry, GSK becomes the first big pharma player to back the AllTrials.net campaign – making all of their clinical trials information publically available for the first time.

Pages